| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T127 |
0-142 |
Sentence |
denotes |
Lopinavir/ritonavir has had the same limitations of use as hydroxychloroquine/chloroquine, with no clear benefits beyond standard care [3,23]. |
| T128 |
143-406 |
Sentence |
denotes |
Considering the uncertainty and the likely increase in gastrointestinal side effects, principal guidelines around the world have not contemplated its use in patients with COVID-19 [4,18,19,20] or have only considered it in the context of a clinical trial [21,22]. |
| T129 |
407-486 |
Sentence |
denotes |
Remdesivir was only considered when patients were enrolled in a clinical trial. |
| T130 |
487-703 |
Sentence |
denotes |
Randomized controlled trials have reported that remdesivir reduces the duration of mechanical ventilation and time to symptom resolution, but its effect on mortality and other adverse outcomes remains uncertain [24]. |
| T131 |
704-766 |
Sentence |
denotes |
Other antivirals were not routinely included in our protocols. |
| T132 |
767-978 |
Sentence |
denotes |
Antiviral agents such as oseltamivir, umifenovir, favipiravir, or ribavirin as well as miscellaneous agents such as interferon-α or interferon-β are being studied for use as possible treatments for COVID-19 [3]. |
| T133 |
979-1149 |
Sentence |
denotes |
Currently, principal guidelines have either not reported any recommendation for their use [4,18,19,20,21] or have suggested not using them in patients with COVID-19 [22]. |
